Abbott Laboratories (ABT)

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.

Medical device company Penumbra (NYSE:PEN) will be reporting results tomorrow after the bell. Here’s what investors should know.

Medical device company ResMed (NYSE:RMD) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Medical device company Boston Scientific (NYSE:BSX) will be reporting results tomorrow before market open. Here’s what to look for.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results tomorrow after market close. Here’s what investors should know.

The company is focused on nutritionals, diagnostics, generic drugs, and medical devices.

Turn $180 into $7M? These 5 Dividend Aristocrats show how it's possible.

Abbott Laboratories stock price is on track to hit a new high in 2025 and could do it before the end of the first half. Dividends and buybacks help.

U.S. stock futures rose on Thursday ahead of the long weekend, with Good Friday falling on April 18 and Easter Sunday on April 20.

Amidst the tariff chaos, we may get clues from one of the most defensive sectors of the market-healthcare stocks.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Powell says tariffs could lead to higher inflation and slower growth, but Fed won't intervene in market losses. Stocks tumble, gold prices rise.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) jumped 5.4% in the morning session after the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop. 

U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip export restrictions to China.

Abbott reaffirmed its full-year 2025 financial guidance and expects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25.

Abbott reaffirmed its 2025 EPS guidance supported by strong Diabetes and Nutrition growth.

Abbott stock slipped early Wednesday after the health giant reported light first-quarter sales, though profit beat views.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4% year on year to $10.36 billion. Its non-GAAP profit of $1.09 per share was 1.7% above analysts’ consensus estimates.

Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.